There is a lack of consensus among experts and professional organizations whether HCV screening in pregnant women should be risk based or universal.
Overall, 1.7 and 1.0% of all US adults HCV antibody-positive and HCV RNA-positive.
The introduction of DAAs has caused a significant reduction in the percentage of liver transplant recipients for HCV who are viremic after surgery.
Universal 1-time screening for chronic HCV infection is cost-effective compared with no screening or with birth cohort-based screening alone.
The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) released updates guidelines for treating hepatitis C infection.
One of the goals of the US Department of Health and Human Services National Viral Hepatitis Action Plan is to eliminate mother-to-infant transmission of HCV infection.
Investigators examined treatment response of sofosbuvir-based DAA in patients with chronic hepatitis C with compensated liver cirrhosis in a community care setting.
Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.
Inspection at the VIP Spa in Albuquerque detected practices that might spread HIV or hepatitis B and C.
Curing HCV infection with direct-acting antiretrovirals is associated with regression of liver fibrosis for most patients.
The researchers found a significant difference in mean time to direct-acting antiviral agent treatment among participants with public insurance payers compared with private insurance payers.
The neuropsychiatric symptoms associated with HCV infection are likely caused by the body's response to the virus' effects on brain function.
Direct-acting antivirals are safe and effective in African-American patients with chronic HCV.
There is an opportunity to improve HCV treatment rates for people who inject drugs by integrating DAA therapy into current models of community-based addiction.
All 20 recipients experienced HCV cure, good quality of life, excellent renal function.
Investigators added hepatitis C virus and HIV screening tests to standard trauma activation laboratory orders.
Coordinated treatment programs may improve treatment outcomes in patients with hepatitis C infection.
Project ECHO at Los Angeles Christian Health Center contributes to improved care of HCV in underserved populations.
Successful DAA therapy may lead to cognitive improvement in several domains in HCV-infected patients.
Low screening rate seen at same time as increase in hepatitis C virus prevalence among pregnant women
The Respectful & Equitable Access to Comprehensive Healthcare program obtained 93% of prior authorization approvals for hepatitis C medications.
A proposed novel Medicaid purchasing strategy is anticipated to increase access to medications that can eradicate hepatitis C virus infection without increasing costs at the state and federal levels.
Patients with mild, moderate renal impairment showed improvement in renal biomarkers over one year
A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.
In this retrospective study, only a fraction of infants receiving well-child care at the study institution were screened for hepatitis C, despite being born to mothers with a known history of hepatitis C virus infection.
Screening prevalence 11.5 to 12.8%; similar rate for cohort born from 1966 to 1985
In this large, real-world cohort of patients with chronic hepatitis C virus infection, equivalent sustained virologic response rates were found with both 8-week and 12-week treatment.
Direct-acting antivirals improved the survival of patients undergoing liver transplantation for HCV-related liver disease.
Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.
Prophylaxis safely, effectively prevents HCV transmittance in noninfected patients receiving kidney transplants from HCV-positive donors.